Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 12/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21313419 | 0.89 | SNCA (0.43) | CSF1RSNCALPLLIPGCA1 | |
| SCHEMBL1560148 | 0.89 | ALDH1A1 (0.46) | CSF1RSNCALPLLIPGCA1 | |
| SCHEMBL28423211 | 0.87 | PGR (0.35) | CSF1RSNCALPLLIPGCA1 | |
| SCHEMBL11910688 | 0.82 | LPL (0.45) | CSF1RLPLLIPGCA1CA2 | |
| SCHEMBL4020523 | 0.82 | LPL (0.45) | CSF1RLPLLIPGCA1CA2 | |
| SCHEMBL1164931 | 0.81 | SNCA (0.39) | CSF1RSNCALPLLIPGCA1 | |
| SCHEMBL4252418 | 0.81 | SNCA (0.39) | SNCALPLLIPGCA1CA2 | |
| SCHEMBL4242311 | 0.81 | SNCA (0.39) | CSF1RSNCALPLLIPGCA1 | |
| SCHEMBL15649176 | 0.81 | CA1 (0.41) | CSF1RSNCALPLLIPGCA1 | |
| SCHEMBL16815511 | 0.81 | LPL (0.46) | CSF1RSNCALPLLIPGCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| CN-115448957-A | Novel tetradentate platinum complexes | 通用显示公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-111732611-B | Novel tetradentate platinum complexes | 通用显示公司 | 2022-08-23 | — | — | CN | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| WO-2012116231-A2 | NOVEL TETRADENTATE PLATINUM COMPLEXES | UNIVERSAL DISPLAY CORPORATION (US) | 2012-08-30 | — | — | WO | disclosed |
| US-20120065154-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065154-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20090181988-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181988-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-16 | — | — | US | disclosed |
| US-7429596-B2 | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429596-B2 | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-30 | — | — | US | disclosed |
| US-7329769-B2 | Catalytic boronate ester synthesis from boron reagents and hydrocarbons | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329769-B2 | Catalytic boronate ester synthesis from boron reagents and hydrocarbons | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153710-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | CSF1R 3728/4885SNCA 3051/4885LPL 2655/4885 |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | CSF1R 3924/4885SNCA 4236/4885LPL 3322/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | CSF1R 1769/4885SNCA 1718/4885LPL 2197/4885 |
| US-20090181988-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | DPYD, DHODH, DLD | CSF1R 2386/4885SNCA 3533/4885LPL 1784/4885 |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | CSF1R 3312/4885SNCA 1368/4885LPL 2103/4885 |
| US-20120065154-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | DPYD, DHODH, DLD | CSF1R 2386/4885SNCA 3533/4885LPL 1784/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | CSF1R 3730/4885SNCA 3052/4885LPL 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.